Profil
Brian J.
Groch formerly worked at Exsto Therapeutics, as President & Chief Executive Officer, Phadia US, Inc., as Director-Health Policy, Veru, Inc., as Chief Commercial Officer & Executive VP from 2017 to 2018, Dendreon Corp., as Head-Market Access from 2010 to 2013, Telesta Therapeutics, Inc., as Chief Commercial Officer from 2015 to 2016, Acasti Pharma, Inc., as Chief Commercial Officer from 2018 to 2020, and Horizon Therapeutics, Inc., as VP-Commercial Operations & Market Access from 2014 to 2015.
Mr. Groch received his undergraduate degree and graduate degree from Central Michigan University.
Anciens postes connus de Brian J. Groch
| Sociétés | Poste | Fin |
|---|---|---|
| ACASTI PHARMA INC. | Corporate Officer/Principal | 31/12/2020 |
| VERU INC. | Corporate Officer/Principal | 16/04/2018 |
| TELESTA THERAPEUTICS INC | Corporate Officer/Principal | 01/12/2016 |
Horizon Therapeutics, Inc.
 Horizon Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Horizon Therapeutics is a late stage biopharmaceutical company focused on the development of prescription drugs for mild to moderate pain relief. It is creating novel therapies through innovative combinations of existing pharmaceutical products. The Company is building a portfolio of proprietary formulations that seek to improve safety, efficacy, and patient compliance. | Corporate Officer/Principal | 01/01/2015 |
| DENDREON CORPORATION | Corporate Officer/Principal | 01/01/2013 |
Formation de Brian J. Groch
| Central Michigan University | Graduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| VERU INC. | Health Technology |
| ACASTI PHARMA INC. | Health Technology |
| Entreprise privées | 5 |
|---|---|
Dendreon Corp.
 Dendreon Corp. Medical SpecialtiesHealth Technology Dendreon Corp. discovers, develops and commercializes novel products for the treatment of cancer. The company applies its expertise in antigen identification, engineering and cell processing to produce active cellular immunotherapy ACI product candidates designed to stimulate an immune response in a variety of tumor types. It is an exploring the application of additional ACI product candidates and small molecules for the potential treatment of a variety of cancers. Dendreon was founded by Christopher S. Henney, Edgar G. Engleman and Samuel Strober in 1992 and is headquartered in Seattle, WA. | Health Technology |
Telesta Therapeutics, Inc.
 Telesta Therapeutics, Inc. Pharmaceuticals: OtherHealth Technology Telesta Therapeutics, Inc. is a biotechnology company, which focuses on the licensing/acquisition and development of transformational therapeutics for the treatment of serious human diseases, such as cancer, immune diseases, and targeted rare diseases. The company was founded by Graeme McRae in 1979 and is headquartered in Pointe-Claire, Canada. | Health Technology |
Horizon Therapeutics, Inc.
Horizon Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Horizon Therapeutics is a late stage biopharmaceutical company focused on the development of prescription drugs for mild to moderate pain relief. It is creating novel therapies through innovative combinations of existing pharmaceutical products. The Company is building a portfolio of proprietary formulations that seek to improve safety, efficacy, and patient compliance. | Health Technology |
Phadia US, Inc.
 Phadia US, Inc. BiotechnologyHealth Technology Part of Thermo Fisher Scientific, Inc., Phadia US, Inc. engages in the research and development of blood testing products and instrumentation that aid in the diagnosis of allergy. The company is based in Portage, MI. | Health Technology |
| Exsto Therapeutics |
